文献速递妇科肿瘤

尼拉帕利联合帕博利珠单抗治疗复发性铂耐药卵巢癌的单臂1期和2期试验

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
PubMed 文献 · JAMA Oncol · 2019-01-01

TOPACIO/KEYNOTE-162开放标签单臂1/2期研究评估尼拉帕利联合帕博利珠单抗治疗复发性卵巢癌。推荐2期剂量为尼拉帕利200mg每日一次口服联合帕博利珠单抗200mg每21天周期第1天静脉给药。合并62例卵巢癌患者(中位年龄60岁),可评估60例,客观缓解率18%(90%CI 11%-29%),疾病控制率65%(90%CI 54%-75%)。

要点

  • 推荐2期剂量:尼拉帕利200mg每日一次口服联合帕博利珠单抗200mg每21天周期第1天静脉给药。
  • 卵巢癌合并队列60例可评估患者中,客观缓解率18%(90%CI 11%-29%),疾病控制率65%(90%CI 54%-75%)。
  • 缓解在铂类敏感性、既往贝伐珠单抗治疗、肿瘤BRCA或同源重组缺陷生物标志物状态各亚组中一致。

核心结论

  • 尼拉帕利联合帕博利珠单抗可耐受,对治疗选择有限的卵巢癌患者显示出有前景的抗肿瘤活性,无论铂类状态、生物标志物状态或既往贝伐珠单抗治疗如何。
  • 在无肿瘤BRCA突变或非同源重组缺陷癌症患者中的缓解率高于任一单药治疗的预期。

研究设计与样本

  • TOPACIO/KEYNOTE-162试验为开放标签、单臂1期和2期研究,入组晚期或转移性三阴性乳腺癌或复发性卵巢癌女性,不论BRCA突变状态。
  • 1期入组14例患者(9例卵巢癌和5例三阴性乳腺癌),2期入组53例卵巢癌患者,合并卵巢癌队列共62例(中位年龄60岁,范围46-83岁)。
  • 中位随访12.4个月(范围1.2至≥23.0个月),数据收集自2016年4月15日至2018年9月4日,数据截止2018年9月4日,分析自2018年9月4日至2019年1月30日。

主要发现

  • 卵巢癌合并可评估人群(62例中60例)客观缓解率为18%(90%CI 11%-29%),疾病控制率为65%(90%CI 54%-75%)。
  • 最佳总体缓解包括3例(5%)确认完全缓解、8例(13%)确认部分缓解、28例(47%)疾病稳定和20例(33%)疾病进展。
  • 基于铂类化疗敏感性、既往贝伐珠单抗治疗或肿瘤BRCA或同源重组缺陷生物标志物状态的亚组间客观缓解率一致。
  • 中位缓解持续时间未达到(范围4.2至≥14.5个月)。
  • 数据截止时,2例缓解患者和1例疾病稳定患者继续接受治疗。

关键数值与推荐

  • 推荐2期剂量为尼拉帕利200mg每日一次口服和帕博利珠单抗200mg每21天周期第1天静脉给药。
  • 1期主要目标为评估剂量限制性毒性效应并确定推荐2期剂量和给药方案;2期主要目标为评估客观缓解率(完全加部分缓解)。
  • 因1期和2期卵巢癌人群相似,数据合并进行整合疗效分析。

临床怎么用

  • 作者认为尼拉帕利联合帕博利珠单抗可耐受,对治疗选择有限的卵巢癌患者显示出有前景的抗肿瘤活性,无论铂类状态、生物标志物状态或既往贝伐珠单抗治疗如何。
  • 作者指出在无肿瘤BRCA突变或非同源重组缺陷癌症患者中的缓解率高于任一单药治疗的预期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with recurrent ovarian carcinoma frequently develop resistance to platinum-based chemotherapy, at which time treatment options become limited. OBJECTIVE: To evaluate the poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor niraparib combined with pembrolizumab in patients with recurrent ovarian carcinoma. DESIGN, SETTING, AND PARTICIPANTS: The TOPACIO/KEYNOTE-162 (Niraparib in Combination With Pembrolizumab in Patients With Triple-Negative Breast Cancer or Ovarian Cancer) trial, an open-label, single-arm phases 1 and 2 study enrolled women with advanced or metastatic triple-negative breast cancer (TNBC) or recurrent ovarian carcinoma, irrespective of BRCA mutation status. Median follow-up was 12.4 months (range, 1.2 to ≥23.0 months). Data were collected from April 15, 2016, through September 4, 2018, with September 4, 2018, as a data cutoff, and analyzed from September 4, 2018, through January 30, 2019. INTERVENTIONS: The recommended phase 2 dose (RP2D) was 200 mg of oral niraparib once daily and 200 mg of intravenous pembrolizumab on day 1 of each 21-day cycle. MAIN OUTCOMES AND MEASURES: The primary objectives of phase 1 were to evaluate dose-limiting toxic effects and establish the RP2D and dosing schedule. The primary objective of phase 2 was to assess objective response rate (ORR; complete plus partial responses). Results from the phase 1 ovarian carcinoma and TNBC cohorts and phase 2 ovarian carcinoma cohort are reported. Because of the similarity in the phase 1 and 2 ovarian carcinoma populations, the data were pooled to perform an integrated efficacy analysis. RESULTS: Fourteen patients (9 with ovarian carcinoma and 5 with TNBC) in phase 1 and 53 patients with ovarian carcinoma in phase 2 were enrolled, for a pooled ovarian carcinoma cohort of 62 patients (median age, 60 years [range, 46-83 years]). In the integrated efficacy phases 1 and 2 ovarian carcinoma population (60 of 62 evaluable patients), ORR was 18% (90% CI, 11%-29%), with a disease control rate of 65% (90% CI, 54%-75%), including 3 (5%) with confirmed complete responses, 8 (13%) with confirmed partial responses, 28 (47%) with stable disease, and 20 (33%) with progressive disease. The ORRs were consistent across subgroups based on platinum-based chemotherapy sensitivity, previous bevacizumab treatment, or tumor BRCA or homologous recombination deficiency (HRD) biomarker status. Median duration of response was not reached (range, 4.2 to ≥14.5 months). At data cutoff, 2 patients with a response and 1 patient with stable disease continued to receive treatment. CONCLUSIONS AND RELEVANCE: Niraparib in combination with pembrolizumab is tolerable, with promising antitumor activity for patients with ovarian carcinoma who have limited treatment options regardless of platinum status, biomarker status, or prior treatment with bevacizumab. Responses in patients without tumor BRCA mutations or non-HRD cancers were higher than expected with either agent as monotherapy. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02657889.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol. 2019. PMID: 31194228. doi:10.1001/jamaoncol.2019.1048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。